A predictive model to estimate the pretest probability of metastasis in patients with osteosarcoma

Abstract

Osteosarcomas (OSs) represent a huge challenge to improve the overall survival, especially in metastatic patients. Increasing evidence indicates that both tumor-associated elements but also on host-associated elements are under a remarkable effect on the prognosis of cancer patients, especially systemic inflammatory response. By analyzing a series prognosis of factors, including age, gender, primary tumor size, tumor location, tumor grade, and histological classification, monocyte ratio, and NLR ratio, a clinical predictive model was established by using stepwise logistic regression involved circulating leukocyte to compute the estimated probabilities of metastases for OS patients. The clinical predictive model was described by the following equations: probability of developing metastases = ex/(1 + ex), x = −2.150 + (1.680 × monocyte ratio) + (1.533 × NLR ratio), where is the base of the natural logarithm, the assignment to each of the 2 variables is 1 if the ratio >1 (otherwise 0). The calculated AUC of the receiver-operating characteristic curve as 0.793 revealed well accuracy of this model (95% CI, 0.740–0.845). The predicted probabilities that we generated with the cross-validation procedure had a similar AUC (0.743; 95% CI, 0.684–0.803). The present model could be used to improve the outcomes of the metastases by developing a predictive model considering circulating leukocyte influence to estimate the pretest probability of developing metastases in patients with OS.

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

“…With advanced chemotherapy techniques, the 5-year survival rate is approximately 60-70% in OS patients without distant metastasis (5). However, the 5-year survival rate is lower than 30% for OS patients with distant metastasis (6). Thus, studies concerning the molecular mechanisms underlying OS carcinogenesis are vital for further clinical treatment.…”

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

“…The lack of effective biomarkers is one of the most crucial problems for osteosarcoma, which is the most frequent type of bone malignancies and the leading cause of cancer related mortality in children and young adults [ 1 , 2 ]. Despite current advancements in diagnosis and therapy of osteosarcoma, the 5-year survival rate of this disease is still poor, and becomes unacceptably low for patients with recurrence or distant metastasis [ 3 , 4 ]. Thus, the identification of possible biomarker is urgently needed to improve the diagnosis and prognostic predictions of osteosarcoma.…”

Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma

“…Metastatic lesions found in the lung, liver, brain, bone, kidney, and local lymph nodes were defined as metastasis. [ 14 – 18 ] In this study, a meta-analysis was conducted to provide a comprehensive evaluation of the relationship between positive expression of MMP-9 and OS metastasis.…”